10-Q: Decoy Therapeutics Reports Q2 2026 Results, Faces Nasdaq Delisting Risk

Decoy Therapeutics Inc. filed its Q2 2026 Form 10-Q, detailing ongoing operational losses, a significant cash burn, and a new risk of Nasdaq delisting.

Summary

• Decoy Therapeutics Inc. reported its financial results for the second quarter ended June 30, 2026.
• The company continues to operate at a loss, with a net loss of $2.37 million for the quarter and $4.60 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and restricted cash stood at $8.29 million as of June 30, 2026, with management believing it is sufficient to fund operations into late 2026.
• The company faces substantial doubt regarding its ability to continue as a going concern due to recurring losses and lack of product sales revenue.
• A significant risk has emerged regarding potential delisting from the Nasdaq Capital Market due to a new minimum market value of listed securities requirement.
• The company completed a private placement in June 2026, raising approximately $3.5 million in gross proceeds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued operational losses, substantial doubt about its ability to continue as a going concern, and the potential for delisting from Nasdaq.

Positives

• Secured $3.5 million in gross proceeds from a private placement in June 2026.
• Grant revenue of $0.2 million recognized in Q2 2026, primarily from the Gates Foundation grant.
• The company believes its current cash and cash equivalents are sufficient to fund operations into late 2026.
• The merger with Legacy Decoy has created a comprehensive drug development platform integrating expertise in peptide conjugates and small molecule assets.

Negatives

• Net loss of $2.37 million for the three months ended June 30, 2026, and $4.60 million for the six months ended June 30, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Cash used in operating activities was $5.54 million for the six months ended June 30, 2026.
• The company has no products approved for commercial sale and has not generated revenue from product sales.
• The company's common stock is trading at levels below the new proposed Nasdaq minimum market value of listed securities requirement, posing a risk of delisting.

Risks

• Potential delisting from the Nasdaq Capital Market due to the new minimum market value of listed securities requirement.
• Substantial doubt about the company's ability to continue as a going concern.
• The company may be unable to raise additional capital on favorable terms or at all, which could lead to delays or cessation of product development.
• The company's ability to obtain and maintain regulatory approvals for its potential product candidates.
• The potential impact of changes and disruptions at the FDA.
• The company's ability to successfully commercialize its potential product candidates, if approved.

Future Outlook

The company anticipates higher research and development expenses in upcoming quarters as it progresses towards filing an IND application with the FDA or the European equivalent CTA during the first half of 2027. Management believes current cash and cash equivalents will be sufficient to fund operations into late 2026, but acknowledges the need for additional capital to continue development and operations.

Management Comments

• The Company believes the synergies from the Merger are evident in our combined approach to drug development, integrating expertise in peptide conjugates with our small molecule assets.
• This combination enables the Company to address a wider range of diseases and potentially undruggable targets.
• We believe our current cash and cash equivalents will be sufficient to fund our current and restructured operations into late 2026.
• We will need to raise additional capital to continue to fund the further development of product candidates and our operations.

Industry Context

StockSavvy.ai notes that Decoy Therapeutics operates in the highly competitive and capital-intensive biotechnology sector. The company's focus on peptide conjugates and its IMP 3 ACT platform aligns with emerging trends in drug discovery leveraging AI/ML. However, the significant cash burn and ongoing losses are typical for pre-revenue biotech firms, making access to capital and regulatory approvals critical success factors.

Comparison to Industry Standards

• Pre-clinical stage biotechnology companies often experience significant operating losses and rely heavily on external financing, as seen with Decoy Therapeutics.
• The need for substantial capital raises to fund R&D and clinical trials is a common characteristic of the industry.
• The risk of delisting due to market capitalization is a concern for many smaller public biotech companies, especially in volatile market conditions.
• The development timelines for new drug candidates, from pre-clinical to regulatory approval, are lengthy and uncertain, impacting financial projections and cash runway.

Legal Proceedings

• The company is not a party to any material legal proceedings as of the report date.

Related Party Transactions

• As of June 30, 2026, a family member of an officer/founder had an outstanding Demand Note of $83,333 plus accrued interest and an outstanding Promissory Note of $100,000 plus accrued interest. These notes were to be exchanged for Salarius Series B Preferred Stock and were extinguished at the merger closing.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and the risk of delisting from Nasdaq.
• Creditors and suppliers may be impacted by the company's going concern issues and need for future financing.
• Employees may face uncertainty due to the company's financial position and potential need for restructuring or operational changes.

Next Steps

• Advance lead asset into clinical trials using proceeds from the private placement.
• File an IND application with the FDA or the European equivalent CTA during the first half of 2027.
• Seek strategic alternatives for the SP-2577 program, including potential out-licensing.
• Integrate SP-3164 to expand opportunities in creating peptide-based proteolysis targeting chimeras (P-PROTACs).

Key Dates

Recommendation

The company exhibits significant financial distress, including substantial operating losses, doubt about its ability to continue as a going concern, and a high risk of delisting from Nasdaq. While a recent capital raise provides some runway, the ongoing cash burn and lack of revenue generation, coupled with the potential for delisting, present considerable downside risk for investors.

Keywords

biotechnology, drug development, peptide conjugates, IMP 3 ACT platform, clinical trials, oncology, infectious diseases, Nasdaq listing